Cleerly Stock
| Valuation | $729.01M1 |
| Valuation Date | Dec 4, 2024 |
| Implied Valuation | $646.09M |
| Last Price | $7.09 |
| 52-Week High | $7.09 |
| 52-Week Low | $5.20 |
| YTD Return | +25.93% |
| 1-Year Return | +22.24% |
| 3-Year Return | n/a |
| Total Funding | $385M2, 3 |
| Latest Round Amount | $106M2 |
| Latest Round | Series C ext. |
| Funding Rounds | n/a |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Cleerly
Cleerly is a healthcare technology company that uses artificial intelligence to measure coronary artery disease from CT scans. Its FDA-cleared software reads coronary computed tomography angiography images and quantifies how much plaque sits in each artery, what that plaque is made of and how narrowed the vessel is. Two companion products extend that analysis: Cleerly ISCHEMIA estimates whether blood flow is restricted and Cleerly COMPARE tracks how plaque changes between scans. Cleerly makes money by charging hospitals, imaging centers and cardiology practices for each scan it analyzes, which providers bill to Medicare and to commercial insurers such as UnitedHealthcare, Cigna and Aetna under dedicated CPT Category I codes. Founder and chief executive James Min is a cardiologist who directed the Dalio Institute of Cardiovascular Imaging at NewYork-Presbyterian and Weill Cornell Medicine before starting the company.
Invest in Cleerly
Cleerly is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
Related Companies
News
Cleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery Disease
Cleerly and precision medicine company Allelica launched the Cleerly Polygenic Cardiovascular Risk Score Test, a saliva-based test that estimates a patient's inherited predisposition to coronary plaqu...
Cleerly to Debut Customizable Full Text Reports and Present New AI-QCT Research at SCCT2026
Cleerly said it would introduce configurable full text reporting and present six scientific abstracts at the Society of Cardiovascular Computed Tomography's 21st annual meeting.
MemorialCare Heart & Vascular Institute Becomes First Hospital in Los Angeles County to Offer Cleerly AI-Powered Heart Disease Analysis, Quantifying Total Plaque Volume and Soft Plaque
MemorialCare rolled out Cleerly's AI coronary CT analysis across Long Beach Medical Center, Orange Coast Medical Center and other sites in its system. It is the first health system in Los Angeles Coun...
Heartflow Files Patent Infringement Lawsuit Against Cleerly
Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform Heartflow asserts that Cleerly infringed foundational patented technology central to the Hea...
Cleerly to Debut Cleerly PREVIEW and Showcase New AI-QCT Research at ACC.26
Cleerly unveiled Cleerly PREVIEW and presented new AI-enabled quantitative coronary CT research at the American College of Cardiology's 2026 scientific session.
Cleerly AI-QCT Demonstrates High Agreement With Invasive IVUS in INVICTUS Registry
Results from the INVICTUS registry showed Cleerly's AI-based quantitative coronary CT measurements agreed closely with intravascular ultrasound, the invasive reference standard for plaque quantificati...
Aetna Approves Coverage for Cleerly's AI Cardiovascular Imaging Analysis
Aetna added coverage for Cleerly's AI-enabled plaque analysis, extending commercial reimbursement for the technology beyond Medicare and earlier payer decisions.
CVCT 2025: Cleerly Late-Breaking Science Identifies Thresholds of High Plaque Burden in Non-Obstructive CAD that May Carry Greater Risk Than Obstructive Disease
Late-breaking data presented at CVCT 2025 identified plaque burden thresholds in non-obstructive coronary artery disease that carried higher event risk than obstructive disease.
Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025
Cleerly announced an integration with Nuance PowerScribe reporting software and added lesion-level reporting to its platform at the Radiological Society of North America meeting.
AHA 2025 Late-Breaking Science: Cleerly's AI Atherosclerosis Quantification Outperforms Traditional Risk Scoring
Late-breaking research presented at the American Heart Association's 2025 Scientific Sessions found Cleerly's AI quantification of atherosclerosis predicted cardiovascular events better than conventio...
TCT 2025 Late-Breaking Science: Quantitative Assessment of Non-Calcified Plaque Volume Drives Risk for Myocardial Infarction and Death
Data presented at TCT 2025 linked non-calcified plaque volume measured by Cleerly's software to the risk of heart attack and death.
UnitedHealthcare and Cigna Coverage for Cleerly LABS Advanced Plaque Analysis Begins October 1st
DENVER--(BUSINESS WIRE)-- #AI--Cleerly, the leader in AI-based advanced cardiovascular imaging, today announced that groundbreaking coverage policies from UnitedHealthcare and Cigna for Cleerly® LABS™...
Cigna Approves Coverage for Cleerly's AI Cardiovascular Imaging Technology
Cigna issued a coverage policy for Cleerly's AI cardiovascular imaging analysis, adding another large commercial insurer to the company's reimbursement footprint.
Cleerly Demonstrates Significant Cardiovascular Risk Prediction in Late-Breaking Clinical Science at European Society of Cardiology Congress 2025
Cleerly presented late-breaking clinical science at the European Society of Cardiology Congress showing its AI analysis predicted cardiovascular risk.
EviCore Updates Coverage Guidelines to Include Cleerly LABS Plaque Analysis for AI-guided Coronary Imaging
Benefits manager EviCore updated its coverage guidelines to include Cleerly LABS plaque analysis, a step that affects prior authorization for health plans using its criteria.
Cleerly Announces Key Leadership Promotions: Dr. Udo Hoffmann Named Chief Medical, Scientific and AI Officer; Amit Relia Promoted to Chief Regulatory Officer
Cleerly promoted Udo Hoffmann to chief medical, scientific and AI officer and Amit Relia to chief regulatory officer.
AI Meets Value-Based Care: Cleerly and Cardiac Care Alliance Join Forces to Revolutionize Heart Disease Detection
Cleerly partnered with Cardiac Care Alliance to bring its AI coronary CT analysis into value-based cardiology care arrangements.
Cleerly raises $106M from Insight Partners for AI heart health early detection
Cleerly raised a $106 million Series C extension led by Insight Partners with participation from Battery Ventures, about two years after its $223 million Series C. The company told TechCrunch its soft...
Cleerly raises nearly $200 million in fundraise led by T. Rowe Price, Fidelity
Cleerly, a New York-based health tech startup, has raised $192 million in a funding round led by investment firms T. Rowe Price and Fidelity Management & Research Company LLC.